

**Charity Registration No. 19801**

**Company Registration No. 496464 (Republic of Ireland)**

**BREAKTHROUGH CANCER RESEARCH**  
**TRUSTEES' REPORT AND AUDITED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2018**

## BREAKTHROUGH CANCER RESEARCH

### LEGAL AND ADMINISTRATIVE INFORMATION

---

<b>Trustees</b>	Breda O'Sullivan Brendan Buckley Bryan Mohally Derek Power Sean Ryan Doreen O'Mahony Enda Lynch	(Appointed 1 April 2018) (Appointed 1 April 2018)
<b>Secretary</b>	Sean Ryan	
<b>Charity number</b>	19801	
<b>Company number</b>	496464	
<b>Principal address</b>	Glenlee, Western Road, Cork.	
<b>Registered office</b>	Glenlee, Western Road, Cork.	
<b>Auditor</b>	Moore Stephens, Chartered Accountants & Statutory Audit Firm, 83 South Mall, Cork.	
<b>Bankers</b>	Allied Irish Bank College Branch, Cork.	
<b>Solicitors</b>	Ronan Daly Jermyn, 2 Park Place, City Gate Park, Mahon Point, Co. Cork.	

---

# BREAKTHROUGH CANCER RESEARCH

## CONTENTS

---

	<b>Page</b>
Trustees' report	1 - 4
Statement of trustees' responsibilities	5
Independent auditor's report	6 - 8
Statement of financial activities	9
Balance sheet	10
Statement of cash flows	11
Notes to the financial statements	12 - 21

---

## **BREAKTHROUGH CANCER RESEARCH**

### **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)**

#### **FOR THE YEAR ENDED 31 DECEMBER 2018**

---

The trustees present their report and financial statements for the year ended 31 December 2018.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the Companies Act 2014 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015)".

#### **Objectives and activities**

The main object of Breakthrough Cancer Research (BCR), a not-for-profit company, which has charitable status (Registered Charity Number: 20077945, Revenue Number: CHY19801), is the raising and application of money and other resources for the purpose of education and research and development in the field of cancer prevention, diagnosis and treatment.

The activities are funded by receipt of funds from philanthropic supporters, corporate supporters and through individual giving, community fundraising and events.

Breakthrough Cancer Research focuses on:

- funding world-class cancer research into poor prognosis cancer, which are poorly served by current treatment options;
- facilitating collaboration between scientists and clinicians across Ireland and Internationally; and
- translating lab discoveries into new effective treatments for cancer patients.

The company / charity supports research at a number of Irish Host Institutions (e.g. Universities) but also has a historic but arm's length relationship with the translational research centre formerly known as Cork Cancer Research Centre in UCC and significantly funds their relevant programmes.

#### **Achievements and performance**

Significant progress has been made in 2018 against our research goals and priorities to fund research which will positively impact patient treatment and care. BCR continues to provide support to the research community, new treatments for patients and evidence based information and tools to the public and cancer patients. We continue to strengthen existing relationships while expanding our reach and impact both nationally and internationally.

Some highlights of our activities in 2018 include:

Cancer research: In 2018 funding was provided to fund staff / researchers, consumables, infrastructure and equipment for cancer research to improve cancer care and outcomes and with patient benefit at the core. Fourteen project grants were awarded during the year, which aligned with BCR's research priorities to:

- Increase our research investment into poor prognosis cancers and currently incurable cancers prioritising lung, oesophageal, ovarian and pancreatic cancers.
- Continue to significantly invest in research on the role of the immune system in cancer development and identify opportunities to harness the immune system to control and eradicate metastatic cancers.
- Improve integration of cancer research into cancer care in Ireland by prioritising funding for projects and infrastructure with significant clinical engagement / input.
- Continue to discover and develop new therapeutics and surgical approaches / technologies, including increased investment in biological and immuno-therapies.
- Continue to fund research, which aims to improve the effectiveness or specificity of current cancer therapies including investing in biomarkers discovery, nutrition and therapeutic delivery.
- Invest in research-led innovation at every stage of the cancer patient journey from first diagnosis through to treatment, clinical trials and palliative care to improve survival and quality of life.

## BREAKTHROUGH CANCER RESEARCH

### TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

#### FOR THE YEAR ENDED 31 DECEMBER 2018

---

All supported researchers and institutions are encouraged and are successful in leveraging BCR support to secure additional funding from other National and International Funders. One specific way BCR leverages our research funding is a member of the Medical Research Charities Group (MRCG) and our participation in the MRCG-HRB Joint Funding Scheme. This innovative scheme allows us to nominate peer reviewed projects, which fulfill our research priorities and if selected, leverage 50% funding from the Health Research Board (HRB), while providing the additional 50% from the charity. In 2018 we provided funding for the final year of a 3 year project titled: Bacteria in Human Tumours. We also provided the first year of funding for three newly selected multi-year projects which commenced in late 2018; a project on Oesophageal Cancer in Trinity College Dublin, a Lung cancer project in UCC and an Oesophageal Project in UCC. More details on these and other projects, the nine cancer types we targeted and other BCR outputs can be found in our annual report.

We also provided support for the first year of the Dermot Costello Cancer Immunology Fellowship which is being funded with support from the Five For The Fight campaign.

Cancer treatment: The charity also continues to fund the treatment of patients with Electro-Chemotherapy, a non-surgical technique for the treatment of skin based cancers offered upon referral at Cork University Hospital and Mercy University Hospital. Funding is provided for a clinical trial nurse to support trials initiated because of research at the CCRC and for the purchase of probes and micro-needles.

Evidence-based cancer information and education: In 2018 investment was made in activities to provide the cancer patients and the public with evidence-based strategies to lower their cancer risk, identify early signs of cancer and to improve tolerance to cancer treatments including dietary interventions. This included three recipe books, animated videos and oral presentations to schools and companies and in response to the needs / demand of the public, will roll out further in 2019.

Commencing in 2016 and expanding yearly, funds have been provided by BCR to support the development and dissemination of three books providing advice and recipes for patients experiencing cancer induced weight loss. They are titled "Good Nutrition for Cancer Recovery", "Eating Well with Swallowing Difficulties in Cancer" and "Nourishing Your Body during Pancreatic Cancer Treatment". All of these books are provided to the public for free and the development of a fourth recipe book for cancer survivors was supported in 2018, which will be released in 2019.

#### **Financial review**

The results for the year are set out on page 9.

In terms of financial performance for 2018, the BCR can report a surplus of €138,619. This is in line with the financial projections for the year. Income and expenditure were monitored against our annual budget and financial progress was reported in detail to our Board at regular intervals throughout the year.

It is the policy of the company that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to between three and six months' expenditure and with consideration of research funding commitments in the year. In 2019 and 2020 combined there are €667,351 of research commitments which BCR have committed to meet. It is the policy of the company to take on multi-year research commitments which will be met by cash reserves and anticipated future income which are based on conservative projections derived from prior history. The company considers that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the company's current activities while consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

## **BREAKTHROUGH CANCER RESEARCH**

### **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)**

**FOR THE YEAR ENDED 31 DECEMBER 2018**

---

#### **Principal risk and uncertainty**

The main risk facing the company is the financial risk associated with the nature of its revenue source being donations which are dependent on the prevailing economic climate and as such may fluctuate. BCR currently maintains limited reserves.

Internal control risks are minimised by the implementation of procedures for authorisation of all transactions and projects. The company has assessed the major risks to which the company is exposed and are satisfied that systems are in place to mitigate exposure to major risks.

#### **Post reporting date events**

No matters or circumstances have arisen since the end of the financial period which significantly affected or may significantly affect the operations of the company, the results of those operations or the state of affairs of the company in financial years subsequent to the financial period ended 31 December 2018.

#### **Structure, governance and management**

The organisation is a charitable company limited by guarantee. The company does not have a share capital and consequently the liability of members is limited, subject to an undertaking by each member to contribute to the net assets or liabilities of the company on winding up such amounts as may be required, not exceeding €1.

The charity was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association and managed by a Board of who meet several times a year. A Scientific Advisory Committee and Patient Panel provide objective options and insight into the charities research priorities and direction.

Breakthrough Cancer Research demonstrates openness, transparency and integrity to our donors, supporters, volunteers and funding partners by operating rigorously to the triple lock standards set out by the Charity Institute of Ireland - good fundraising, transparent annual reporting and governance. The Board of BCR has formally adopted, is signed up to and is fully committed to achieving the standards contained within the Statement of Guiding Principles for Fundraising. BCR's annual accounts are independently audited every year and we prepare our accounts in accordance with Irish accounting standards and with reference to the Statement of Recommended Practice (SORP) for charities. The Board of BCR has formally adopted and is publicly signed up to the Governance Code for the Community and Voluntary Sector.

The trustees' who served during the year were:

Breda O'Sullivan	
Dr. Declan Farrell	(Resigned 1 April 2018)
Brendan Buckley	
Bryan Mohally	
Derek Power	
Sean Ryan	
Doreen O'Mahony	(Appointed 1 April 2018)
Enda Lynch	(Appointed 1 April 2018)

All of the above are members of the company and guarantee to contribute €1 in the event of winding up.

#### **Administrative Details**

Registered Charity Number: 20077945  
Revenue Number: CHY19801  
Company Number: 496464

#### **Auditor**

In accordance with the Companies Act 2014, section 383(2), Moore Stephens, continue in office as auditors of the company.

**BREAKTHROUGH CANCER RESEARCH**

**TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)**

**FOR THE YEAR ENDED 31 DECEMBER 2018**


---

**Disclosure of information to auditor**


Each of the trustees' in office at the date of approval of this annual report confirms that:

- so far as the trustee is aware, there is no relevant audit information of which the company's auditors are unaware, and
- the trustee has taken all the steps that they ought to have taken as a trustee in order to make themselves aware of any relevant audit information and to establish that the company's auditors are aware of that information.

The trustees' report was approved by the Board of Trustees.



**Bryan Mohally**  
Trustee



**Sean Ryan**  
Trustee



Dated: 26/09/2019

**BREAKTHROUGH CANCER RESEARCH**

**STATEMENT OF TRUSTEES' RESPONSIBILITIES**

**FOR THE YEAR ENDED 31 DECEMBER 2018**

---


The trustees, who are also the directors of Breakthrough Cancer Research for the purpose of company law, are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and Accounting Standards (Ireland Generally Accepted Accounting Practice).


Company Law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the company and of the incoming resources and application of resources, including the income and expenditure, of the company for that year.

In preparing these financial statements, the company:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in operation.

The trustees' are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2014. They also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

  
**Bryan Mohally**  
Trustee  
Dated: 26/09/2019

  
**Sean Ryan**  
Trustee  
Dated: 26/09/2019

## BREAKTHROUGH CANCER RESEARCH

### INDEPENDENT AUDITOR'S REPORT

#### TO THE MEMBERS OF BREAKTHROUGH CANCER RESEARCH

---

#### Opinion

We have audited the financial statements of Breakthrough Cancer Research (the 'company') for the year ended 31 December 2018 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and the notes to the financial statements, including a summary of significant accounting policies. The relevant financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland*.

In our opinion, the financial statements:

- give a true and fair view of the charitable company's affairs as at 31 December 2018 and of its surplus for the year then ended;
- have been properly prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland; and
- have been prepared in accordance with the requirements of the Companies Act 2014.

#### Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (Ireland) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the trustees has not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

#### Other information

The trustees are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

## **BREAKTHROUGH CANCER RESEARCH**

### **INDEPENDENT AUDITOR'S REPORT (CONTINUED)**

#### **TO THE MEMBERS OF BREAKTHROUGH CANCER RESEARCH**

---

#### **Opinions on other matters prescribed by the Companies Act 2014**

Based solely on the work undertaken in the course of the audit, we report that in our opinion:

- the information given in the trustees' Report, which includes the directors' report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the directors' report included within the trustees' report has been prepared in accordance with applicable legal requirements.

We have obtained all the information and explanations which we consider necessary for the purposes of our audit.

In our opinion, the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited, and the financial statements are in agreement with the accounting records.

#### **Matters on which we are required to report by exception**

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the Trustees' Report.

We have nothing to report in respect of our obligation under the Companies Act 2014 to report to you if, in our opinion, the disclosures of directors' remuneration and transactions specified by sections 305 to 312 of the Act are not made.

#### **Responsibilities of trustees**

As explained more fully in the statement of trustees' responsibilities, the trustees, who are also the directors of the company for the purpose of company law, is responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

#### **Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the IAASA's website at: [http://www.iaasa.ie/Publications/Auditing-standards/International-Standards-on-Auditing-for-use-in-Ire/International-Standards-on-Auditing-\(Ireland\)/ISA-700-\(Ireland\)](http://www.iaasa.ie/Publications/Auditing-standards/International-Standards-on-Auditing-for-use-in-Ire/International-Standards-on-Auditing-(Ireland)/ISA-700-(Ireland)). This description forms part of our auditor's report.

**BREAKTHROUGH CANCER RESEARCH**

**INDEPENDENT AUDITOR'S REPORT (CONTINUED)**

**TO THE MEMBERS OF BREAKTHROUGH CANCER RESEARCH**

---

**The purpose of our audit work and to whom we owe our responsibilities**

This report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.



**John Callaghan**

for and on behalf of Moore  
Chartered Accountants &  
Statutory Audit Firm,  
83 South Mall,  
Cork.

Date:

*26/11/18*

**BREAKTHROUGH CANCER RESEARCH**

**STATEMENT OF FINANCIAL ACTIVITIES  
INCLUDING INCOME AND EXPENDITURE ACCOUNT**

**FOR THE YEAR ENDED 31 DECEMBER 2018**

	Notes	Unrestricted funds 2018 €	Restricted funds 2018 €	Total 2018 €	Total 2017 €
<b><u>Income from:</u></b>					
Legacies	3	7,702	-	7,702	176,000
Charitable activities	4	981,839	327,005	1,308,844	1,135,607
<b>Total income</b>		<u>989,541</u>	<u>327,005</u>	<u>1,316,546</u>	<u>1,311,607</u>
<b><u>Expenditure on:</u></b>					
Raising funds	5	223,161	-	223,161	355,004
Charitable activities	6	174,843	-	174,843	150,510
Research costs	8	523,309	256,614	779,923	327,239
<b>Total resources expended</b>		<u>921,313</u>	<u>256,614</u>	<u>1,177,927</u>	<u>832,753</u>
<b>Net income for the year/ Net movement in funds</b>		68,228	70,391	138,619	478,854
Fund balances at 1 January		<u>374,672</u>	<u>260,436</u>	<u>635,108</u>	<u>156,254</u>
<b>Fund balances at 31 December</b>		<u><u>442,900</u></u>	<u><u>330,827</u></u>	<u><u>773,727</u></u>	<u><u>635,108</u></u>


**BREAKTHROUGH CANCER RESEARCH**


**BALANCE SHEET**

**AS AT 31 DECEMBER 2018**

	Notes	2018		2017	
		€	€	€	€
<b>Fixed assets</b>					
Tangible assets	11		1,781		1,737
<b>Current assets</b>					
Debtors	13	99,111		390,390	
Cash at bank and in hand		849,394		434,896	
		<u>948,505</u>		<u>825,286</u>	
<b>Creditors: amounts falling due within one year</b>	14	<u>(176,559)</u>		<u>(191,915)</u>	
Net current assets			771,946		633,371
<b>Total assets less current liabilities</b>			<u>773,727</u>		<u>635,108</u>
<b>Income funds</b>					
Restricted funds	15		330,827		260,436
Unrestricted funds			442,900		374,672
			<u>773,727</u>		<u>635,108</u>

The financial statements were approved by the Trustees on 26/09/2017

  
 Bryan Mohally  
 Trustee

  
 Sean Ryan  
 Trustee

**BREAKTHROUGH CANCER RESEARCH****STATEMENT OF CASH FLOWS****FOR THE YEAR ENDED 31 DECEMBER 2018**

---

	Notes	2018		2017	
		€	€	€	€
<b>Cash flows from operating activities</b>					
Cash generated from/(absorbed by) operations	20		416,384		(67,161)
<b>Investing activities</b>					
Purchase of tangible fixed assets		(1,886)		-	
<b>Net cash used in investing activities</b>			(1,886)		-
<b>Net cash used in financing activities</b>			-		-
<b>Net increase/(decrease) in cash and cash equivalents</b>			414,498		(67,161)
Cash and cash equivalents at beginning of year			434,896		502,057
<b>Cash and cash equivalents at end of year</b>			<u>849,394</u>		<u>434,896</u>

---

**BREAKTHROUGH CANCER RESEARCH**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2018**

---

**1 Accounting policies**

**Charity information**

Breakthrough Cancer Research is a company limited by guarantee and has no share capital. In the event of the company being wound up, the liability in respect of the guarantee is limited to €1 per member of the charity.

**1.1 Accounting convention**

These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102"), "Accounting and Reporting by Charities" the Statement of Recommended Practice for charities applying FRS102 and the requirements of the Companies Act 2014. The company is a Public Benefit Entity as defined by FRS102.

The financial statements are prepared in euros, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest €.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

**1.2 Going concern**

At the time of approving the financial statements, the trustees has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

**1.3 Charitable funds**

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

**1.4 Incoming resources**

Income is recognised when the company is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Legacies are recognised on receipt or otherwise if the company has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

Unrestricted funds are available to spend on activities that further any of the purposes of the charity. Restricted funds are donations which the donor has specified are to be solely used for particular areas of the company's work or for specific artistic projects being undertaken by the company.

**1.5 Resources expended**

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Support costs include back office costs, finance, personnel, payroll and governance costs which support the company's activities. These costs have been allocated between cost of raising funds and expenditure on charitable activities. The bases on which support costs have been allocated are set out in note 7.

## BREAKTHROUGH CANCER RESEARCH

### NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2018

---

#### 1 Accounting policies

(Continued)

##### 1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings	20% S.L
Computers	33.33% S.L

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

##### 1.7 Impairment of fixed assets

At each reporting end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

##### 1.8 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

##### 1.9 Financial instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

##### **Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

## BREAKTHROUGH CANCER RESEARCH

### NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2018

#### 1 Accounting policies

(Continued)

##### **Basic financial liabilities**

Basic financial liabilities, including trade and other payables, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Accounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade payables are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

##### **Derecognition of financial liabilities**

Financial liabilities are derecognised when the company's contractual obligations expire or are discharged or cancelled.

#### 2 Critical accounting estimates and judgements

In the application of the company's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

##### **Critical judgements**

The trustees are of the view that there are no judgements (apart from those involving estimates) in applying their accounting policies that have had a significant effect on amounts recognised in the financial statements.

##### **Key sources of estimation uncertainty**

The trustees are of the view that there are no estimates or assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities.

#### 3 Legacies

	Total	Total
	2018	2017
	€	€
Legacies receivable	7,702	176,000

**BREAKTHROUGH CANCER RESEARCH**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**

**FOR THE YEAR ENDED 31 DECEMBER 2018**

**4 Charitable activities**

	<b>Corporate Funds 2018 €</b>	<b>Challenges &amp; Events 2018 €</b>	<b>Communities 2018 €</b>	<b>Individual Giving 2018 €</b>	<b>Campaigns 2018 €</b>	<b>Major Gifts 2018 €</b>	<b>Total 2018 €</b>	<b>Total 2017 €</b>
Income from charitable activities	330,123	204,842	245,137	345,143	13,947	169,652	1,308,844	1,135,607
<b>Analysis by fund</b>								
Unrestricted funds	247,107	170,707	245,137	191,094	13,947	113,847	981,839	955,193
Restricted funds	83,016	34,135	-	154,049	-	55,805	327,005	180,414
	330,123	204,842	245,137	345,143	13,947	169,652	1,308,844	1,135,607
<b>For the year ended 31 December 2017</b>								
Unrestricted funds	180,994	139,587	249,075	307,852	17,685	60,000		955,193
Restricted funds	37,778	31,917	-	51,662	18,698	40,359		180,414
	218,772	171,504	249,075	359,514	36,383	100,359		1,135,607

**BREAKTHROUGH CANCER RESEARCH****NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)****FOR THE YEAR ENDED 31 DECEMBER 2018****5 Raising funds**

	<b>Total 2018 €</b>	<b>Total 2017 €</b>
<u>Fundraising and publicity</u>		
Challenges and event costs	43,770	63,974
Campaign costs	6,926	8,476
Corporate costs	2,554	3,767
Direct marketing costs	55,937	56,122
Community costs	1,717	10,018
Staff costs	112,257	212,647
	<hr/>	<hr/>
Fundraising and publicity	223,161	355,004
	<hr/>	<hr/>
	<b>223,161</b>	<b>355,004</b>
	<hr/> <hr/>	<hr/> <hr/>

**6 Charitable activities**

	<b>Total 2018 €</b>	<b>Total 2017 €</b>
Depreciation and impairment	1,842	1,737
Print and Stationery	20,661	13,259
Advertising	19,171	10,130
Sundry Expenses	1,833	1,205
	<hr/>	<hr/>
	43,507	26,331
	<hr/>	<hr/>
Share of support costs (see note 7)	110,441	103,174
Share of governance costs (see note 7)	20,895	21,005
	<hr/>	<hr/>
	<b>174,843</b>	<b>150,510</b>
	<hr/> <hr/>	<hr/> <hr/>

**BREAKTHROUGH CANCER RESEARCH**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**

**FOR THE YEAR ENDED 31 DECEMBER 2018**

**7 Support costs**

	Support costs €	Governance costs €	2018 €	2017 €
Staff costs	43,426	13,524	56,950	61,022
Rent	22,000	-	22,000	18,850
Power, Light and Heat	5,453	-	5,453	5,100
Insurance	5,550	-	5,550	5,410
Computer Costs	15,324	-	15,324	11,069
Motor & Travel Costs	1,358	-	1,358	2,081
Subscriptions	6,646	-	6,646	4,788
Bank Charges	2,333	-	2,333	2,720
Office Costs	3,673	-	3,673	2,654
Telephone Costs	4,678	-	4,678	4,480
Audit fees	-	5,490	5,490	5,535
Legal and professional	-	1,881	1,881	470
	<u>110,441</u>	<u>20,895</u>	<u>131,336</u>	<u>124,179</u>
Analysed between Charitable activities	<u>110,441</u>	<u>20,895</u>	<u>131,336</u>	<u>124,179</u>

**8 Research costs**

	Unrestricted funds 2018 €	Restricted funds 2018 €	Total 2018 €	Total 2017 €
General research	409,425	256,614	666,039	236,618
Education and information	75,564	-	75,564	90,621
Research wages and salaries	38,320	-	38,320	-
	<u>523,309</u>	<u>256,614</u>	<u>779,923</u>	<u>327,239</u>
<b>For the year ended 31 December 2017</b>	<u>270,729</u>	<u>56,510</u>		<u>327,239</u>

**9 Trustees**

None of the trustees (or any persons connected with them) received any remuneration or benefits from the company during the year.

**BREAKTHROUGH CANCER RESEARCH****NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)****FOR THE YEAR ENDED 31 DECEMBER 2018****10 Employees****Number of employees**

The average monthly number of employees during the year was:

	<b>2018</b>	<b>2017</b>
	<b>Number</b>	<b>Number</b>
Employees	4	4

**Employment costs**

	<b>2018</b>	<b>2017</b>
	<b>€</b>	<b>€</b>
Wages and salaries	205,664	272,341

There were no employees whose annual remuneration was €70,000 or more.

**11 Tangible fixed assets****Current financial year**

	<b>Fixtures and fittings</b>	<b>Computers</b>	<b>Total</b>
	<b>€</b>	<b>€</b>	<b>€</b>
<b>Cost</b>			
At 1 January 2018	8,684	-	8,684
Additions	-	1,886	1,886
At 31 December 2018	8,684	1,886	10,570
<b>Depreciation and impairment</b>			
At 1 January 2018	6,947	-	6,947
Depreciation charged in the year	1,737	105	1,842
At 31 December 2018	8,684	105	8,789
<b>Carrying amount</b>			
At 31 December 2018	-	1,781	1,781
At 31 December 2017	1,737	-	1,737

**BREAKTHROUGH CANCER RESEARCH**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 31 DECEMBER 2018**

<b>11 Tangible fixed assets</b>	<b>(Continued)</b>		
<i>Prior financial year</i>	<b>Fixtures and fittings</b>	<b>Computers</b>	<b>Total</b>
	€	€	€
<b>Cost</b>			
At 1 January 2017	8,684	-	8,684
At 31 December 2017	8,684	-	8,684
<b>Depreciation and impairment</b>			
At 1 January 2017	5,210	-	5,210
Depreciation charged in the year	1,737	-	1,737
At 31 December 2017	6,947	-	6,947
<b>Carrying amount</b>			
At 31 December 2017	1,737	-	1,737
At 31 December 2016	3,474	-	3,474
<b>12 Financial instruments</b>		<b>2018</b>	<b>2017</b>
		€	€
<b>Carrying amount of financial assets</b>			
Debt instruments measured at amortised cost		99,111	390,390
<b>Carrying amount of financial liabilities</b>			
Measured at amortised cost		162,190	179,218
<b>13 Debtors</b>		<b>2018</b>	<b>2017</b>
		€	€
<b>Amounts falling due within one year:</b>			
Trade debtors		99,111	390,390
<b>14 Creditors: amounts falling due within one year</b>		<b>2018</b>	<b>2017</b>
		€	€
Other taxation and social security		14,369	12,697
Trade creditors		34,700	18,190
Accruals and deferred income		127,490	161,028
		176,559	191,915

**BREAKTHROUGH CANCER RESEARCH**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**

**FOR THE YEAR ENDED 31 DECEMBER 2018**

**15 Restricted funds**

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	<b>Balance at 1 January 2018</b>	<b>Movement in funds</b>		<b>Balance at 31 December 2018</b>
	<b>€</b>	<b>Incoming resources</b>	<b>Resources expended</b>	<b>€</b>
Clinical cancer chair	136,532	-	-	136,532
Immuno-melanoma appeal	-	37,230	(23,825)	13,405
Osteosarcoma appeal	-	94,434	(40,957)	53,477
Ovarian appeal	19,152	19,500	-	38,652
Pancreatic (T Daly)	7,917	14,635	(22,552)	-
Tumor Immunology (5FTF)	96,835	161,206	(169,280)	88,761
	<u>260,436</u>	<u>327,005</u>	<u>(256,614)</u>	<u>330,827</u>

**16 Analysis of net assets between funds**

	<b>General Funds 2018</b>	<b>Restricted Funds 2018</b>	<b>Total 2018</b>	<b>Total 2017</b>
	<b>€</b>	<b>€</b>	<b>€</b>	<b>€</b>
Fund balances at 31 December 2018 are represented by:				
Tangible assets	1,781	-	1,781	1,737
Current assets/(liabilities)	441,119	330,827	771,946	633,371
	<u>442,900</u>	<u>330,827</u>	<u>773,727</u>	<u>635,108</u>

**17 Committed research funds**

At 31 December 2018 the company had committed to certain research activities for 2019 and 2020 in the amount of €667,351.

**18 Events after the reporting date**

No matters or circumstances have arisen since the end of the financial period which significantly affected or may significantly affect the operations of the company, the results of those operations or the state of affairs of the company in financial years subsequent to the financial period ended 31 December 2018.

**19 Related party transactions**

There were no disclosable related party transactions during the year (2017 - none).

**BREAKTHROUGH CANCER RESEARCH**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**

**FOR THE YEAR ENDED 31 DECEMBER 2018**

---

<b>20</b>	<b>Cash generated from operations</b>	<b>2018</b>	<b>2017</b>
		<b>€</b>	<b>€</b>
	Surplus for the year	138,619	478,854
	Adjustments for:		
	Depreciation and impairment of tangible fixed assets	1,842	1,737
	Movements in working capital:		
	Decrease/(increase) in debtors	291,279	(329,599)
	(Decrease) in creditors	(15,356)	(218,153)
	<b>Cash generated from/(absorbed by) operations</b>	<b>416,384</b>	<b>(67,161)</b>
		<u>          </u>	<u>          </u>

**21 Approval of financial statements**

The board of directors approved the financial statements for issue on the 26/09/2019.